资讯

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...
Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.
The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...
Investing.com -- 据周一发布的公告,世界卫生组织(WHO)已建议使用注射型lenacapavir预防艾滋病。 该组织还支持采用艾滋病快速检测的公共卫生方法,以支持长效注射型暴露前预防(PrEP)的推广。
美国食品药品监督管理局于2025年6月18日批准了Yeztugo,这是首个半年一次的艾滋病预防选择。吉利德科学公司已向澳大利亚、巴西、加拿大和欧洲多个国家的监管机构提交了申请。该公司目前的交易价格接近其 InvestingPro ...
KIGALI, July 14 (Xinhua) -- The 13th International AIDS Society (IAS) Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to ...
HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.
Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries. Manufactured by US ...
Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...